Skip to main content
Top

11-09-2024 | Asthma Attack | News

ERS 2024

Depemokimab: a novel, long-acting biological in severe asthma

MedNet.nl: Depemokimab is a new, long-acting biological drug for the treatment of severe eosinophilic asthma. The phase III studies SWIFT-I and SWIFT-II show that this drug leads to a reduction of 58 and 48% respectively in the annual number of exacerbations. 

Related topics

SPONSORED

Targeting COPD with type 2 inflammation: emerging biologic landscape

  • Live
  • Webinar | 03-12-2024 | 19:00 (CET)

LIVE: Tuesday, 3 December 2024, 19:00-20:30 (CET)

Join us for an insightful session tailored for pulmonologists and healthcare professionals eager to enhance their understanding of COPD and the latest advances in biologic therapies. 

Sponsored by:
  • Sanofi
Developed by: Springer Healthcare
Reserve your place

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases